Literature DB >> 16102026

Venous thromboembolism: disease burden, outcomes and risk factors.

J A Heit1.   

Abstract

The epidemiology of venous thromboembolism (VTE) in the community has important implications for VTE prevention and management. This review describes the disease burden (incidence), outcomes (survival, recurrence and complications) and risk factors for deep vein thrombosis and pulmonary embolism occurring in the community. Recent comprehensive studies of the epidemiology of VTE that reported the racial demography and included the full spectrum of disease occurring within a well-defined geographic area over time, separated by event type, incident vs. recurrent event and level of diagnostic certainty, were reviewed. Studies of VTE outcomes had to include a relevant duration of follow-up. VTE incidence among whites of European origin exceeded 1 per 1000; the incidence among persons of African and Asian origin may be higher and lower, respectively. VTE incidence over recent time remains unchanged. Survival after VTE is worse than expected, especially for pulmonary embolism. Thirty percent of patients develop VTE recurrence and venous stasis syndrome. Exposures can identify populations at risk but have a low predictive value for the individual. An acquired or familial thrombophilia may predict the subset of exposed persons who actually develop symptomatic VTE. In conclusion, VTE is a common, lethal disease that recurs frequently and causes serious long-term complications. To improve survival and prevent complications, VTE occurrence must be reduced. Better individual risk stratification is needed in order to modify exposures and target primary and secondary prophylaxis to the person who would benefit most.

Entities:  

Mesh:

Year:  2005        PMID: 16102026     DOI: 10.1111/j.1538-7836.2005.01415.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  118 in total

1.  Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice.

Authors:  M V Joglekar; Jerry Ware; Jin Xu; Malinda E C Fitzgerald; Theodore Kent Gartner
Journal:  Platelets       Date:  2012-06-21       Impact factor: 3.862

2.  Role of clinical and pulmonary computed tomography angiographic parameters in the prediction of short- and long-term mortality in patients with pulmonary embolism.

Authors:  Nasrin Etesamifard; Shapoor Shirani; Yaser Jenab; Masoumeh Lotfi-Tokaldany; Marzieh Pourjafari; Arash Jalali
Journal:  Intern Emerg Med       Date:  2015-12-28       Impact factor: 3.397

3.  Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function--the Tromsø study.

Authors:  Ellen E Brodin; Sigrid K Brækkan; Anders Vik; Jan Brox; John-Bjarne Hansen
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  Mean platelet volume and D-dimer in patients with suspected deep venous thrombosis.

Authors:  Arzu Canan; Siddıka Sezgin Halıcioğlu; Safiye Gürel
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

5.  Increased expressions of integrin subunit β1, β2 and β3 in patients with cancer ------correlation analysis between risk factors of VTE and expression of core proteins.

Authors:  Yanli Song; Lemin Wang; Fan Yang; Guiyuan Li; Qianglin Duan; Zhu Gong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.

Authors:  Scott D Grosse; Richard E Nelson; Kwame A Nyarko; Lisa C Richardson; Gary E Raskob
Journal:  Thromb Res       Date:  2015-11-24       Impact factor: 3.944

7.  Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009).

Authors:  Wei Huang; Robert J Goldberg; Frederick A Anderson; Catarina I Kiefe; Frederick A Spencer
Journal:  Am J Med       Date:  2014-05-06       Impact factor: 4.965

8.  Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Authors:  Hussain R Yusuf; W Craig Hooper; Michele G Beckman; Qing C Zhang; James Tsai; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

9.  Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.

Authors:  Sigrid K Braekkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

Review 10.  Triggers, targets and treatments for thrombosis.

Authors:  Nigel Mackman
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.